Trials / Recruiting
RecruitingNCT06979271
Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Telitacicept in Combination With Tofacitinib
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Zhejiang Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- —
Summary
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telitacicept Tofacitinib | One group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2026-04-30
- Completion
- 2027-04-30
- First posted
- 2025-05-18
- Last updated
- 2025-05-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06979271. Inclusion in this directory is not an endorsement.